China's humanoid robot sector is moving toward public markets amid demos and investor appetite — but the gap between athletic feats and commercial revenue is becoming the central tension as listing dates approach.
Why it matters
Unitree Robotics priced its IPO at 150.8 yuan per share, raising $900 million and valuing the company at approximately $9 billion14. The company launched IPO subscriptions on August 10 on Shanghai's STAR Market12 and one week later unveiled a new humanoid robot that exceeds human athletic records2,5. Separately, Robotera is reportedly weighing a Hong Kong listing that could raise up to $1 billion3. ANALYSIS Together these represent the first real test of whether public investors will pay for humanoid robotics companies that have yet to demonstrate sustained commercial returns. Robotera, which has not yet filed a prospectus, saw its valuation pushed above RMB 10 billion after a RMB 1 billion strategic round in March 2026, followed by an additional $200 million round in May led by SF Group11. The simultaneous listing push suggests that Chinese humanoid firms and their backers view the current window of investor enthusiasm as one they intend to act on — even as skeptics question the path to revenue.
The big picture
Unitree's new robot, nicknamed "Superman," achieved a 2-meter standing high jump and a top speed of 12.66 meters per second with a leg length of 0.85 meters7. The company said the entirely new robot was developed in just over three months and still has significant room for improvement. In April, Unitree's H1 humanoid robot had set a world record with a running speed of 10 meters per second. Unitree said on August 12 that it had produced about 18,000 humanoid robots to date, counting only bionic bipedal humanoids.
Unitree's IPO saw record retail demand on Shanghai's STAR Market, with the online tranche oversubscribed more than 5,000 times, translating to a lot-winning rate of 0.018%. The launch of Superman came one week after Unitree opened IPO subscriptions on August 10.
ANALYSIS The timing is not accidental. Unveiling a headline-grabbing prototype days after subscription launch — and days before shares begin trading — serves a clear market-signaling function, reinforcing the narrative of rapid R&D velocity at precisely the moment retail and institutional investors are forming price expectations.
Meanwhile, Robotera, a Beijing-based humanoid robot maker backed by HongShan and incubated at Tsinghua University, is reportedly weighing a Hong Kong IPO that could raise up to $1 billion. Robotera has not filed for a Hong Kong listing. The company says its robots are already deployed with China Post and SF Express across more than 10 logistics centers. Robotera describes more than 95% self-sufficiency in core components and is targeting more than 1,000 unit deliveries.
ANALYSIS Robotera's logistics deployments with SF Group — which is both investor and customer — represent the closest thing in this cohort to a repeatable commercial use case, distinguishing it from the demo-driven narratives of most peers.
Between the lines
The sector's core tension was captured by CNBC's framing: "skeptics are questioning how long it will take before these robots can move beyond running and acrobatics to perform genuinely useful work". Unitree is pursuing two tracks simultaneously: aggressive price reduction for mass adoption — the G1 base model has dropped to approximately 85,000 yuan, while the R1-Air starts at 29,900 yuan — and high-performance capability demonstration exemplified by the Superman prototype.
ANALYSIS The dual strategy reveals the bind these companies face. Demos attract IPO capital and media attention, but the revenue case depends on affordable, deployable units performing mundane tasks in factories and warehouses. The 29,900-yuan R1-Air and the Superman prototype, as described in Unitree's own product lineup, are aimed at fundamentally different audiences — one must capture margin, the other captures imagination.
Robotera joins a growing line of Chinese robotics firms, including AgiBot, EngineAI, and Rokae Robotics, picking Hong Kong over U.S. markets for their public debuts. Unitree chose Shanghai's STAR Market for its own listing. ◆ The clustering of listings in Hong Kong and Shanghai underscores that Chinese humanoid firms are tapping domestic and regional capital pools where investor appetite for the sector is concentrated.
What's next
Unitree's shares are expected to begin trading on Shanghai's STAR Market later this month. Robotera's IPO timeline remains undefined — no prospectus has been filed — but its funding pace and the broader market environment place it among the most closely watched candidates. Beijing's upcoming World Humanoid Robot Games, featuring over 2,000 robots from 16 countries in events like long jump and tug of war, will provide another showcase9. ◆ The real contest, however, is not athletic. It is whether any of these companies can convert demo-day spectacle into the recurring commercial revenue that public-market investors will eventually demand.